Overview

Pharmacokinetic Interactions of ENG Subdermal Implants With Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

Status:
Not yet recruiting

Trial end date:
2024-02-25

Target enrollment:

Participant gender:

Summary

The purpose of this pharmacokinetic (PK) trial is to evaluate whether the ENG implant, a long-acting birth control method, is tolerable and effective for adults with HIV who are taking long-acting cabotegravir (CAB-LA) and long-acting rilpivirine (RPV-LA). Access to safe and effective birth control for adults with HIV is important because it may result in fewer infants exposed to HIV in the womb or born with HIV. Researchers believe that people of childbearing potential need access to birth control options that do not need to be negotiated with a partner.

Phase:

Phase 4

Details

Lead Sponsor:

AIDS Clinical Trials Group

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Etonogestrel